Stock comparison
Halozyme Therapeutics
Inspire Medical Systems
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
INSP
Inspire Medical Systems
Market cap
$1.26B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | INSP | Winner |
|---|---|---|---|
| Warren Buffett | 79B | 50D | HALO |
| Benjamin Graham | 83A | 37D | HALO |
| Philip Fisher | 65B | 48D | HALO |
| Peter Lynch | 53D | 71B | INSP |
| Joel Greenblatt | 40D | 49D | INSP |
| Charlie Munger | 80C | 32F | HALO |
| Terry Smith | 84A | 33F | HALO |
Side-by-side metrics
| Metric | HALO | INSP |
|---|---|---|
| Market cap | $8.1B | $1.26B |
| P/E (TTM) | 24.0x | 9.2x |
| EV/EBIT | 10.2x | 22.3x |
| ROIC (TTM) | 23.65% | 6.24% |
| Gross margin | 81.24% | 85.78% |
| Net margin | 23.13% | 14.33% |
| Revenue CAGR 5y | 33.23% | 40.6% |
| EPS CAGR 5y | -1.98% | - |
| Debt / Equity | 1.0x | 0.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- Market cap$8.1Bvs $1.26B+84%
- ROIC (TTM)23.65%vs 6.24%+74%
- EV/EBIT10.2xvs 22.3x+54%
- Net margin23.13%vs 14.33%+38%
INSP leads on
- Debt / Equity0.0xvs 1.0x+96%
- P/E (TTM)9.2xvs 24.0x+62%
- Revenue CAGR 5y40.6%vs 33.23%+18%
- Gross margin85.78%vs 81.24%+5%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.